Nikhil Khushalani, MD

Articles by Nikhil Khushalani, MD

1 expert is featured in this series

Nikhil I. Khushalani, MD, of Moffitt Cancer Center in Tampa, Florida, reviews updated efficacy and safety results from the pivotal open-label study of cosibelimab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic cutaneous squamous cell carcinoma, with a median follow-up of at least 2.5 years, as presented at the 2026 ESMO Congress.

Nikhil Khushalani, MD, vice chair, Department of Cutaneous Oncology, Moffitt Cancer Center, discusses the plans for the CA045-001 trial, an international, multicenter study that is comparing bempegaldesleukin plus nivolumab versus nivolumab monotherapy in patients with previously untreated, unresectable, or metastatic melanoma.